Skip to content Skip to sidebar Skip to footer

How AstraZeneca is harnessing AI for drug development


Speaking at the Citywire Elite Companies Awards, AstraZeneca (GB:AZN) director of investor relations Phil Sparks discusses how the pharmaceutical giant is using artificial intelligence (AI) across its business.

He says the company is working with partners to use AI to ‘ingest huge amounts of scientific data… which could help us identify new targets for future medicines’.  

He adds that AI has the potential to map out people’s medical future – and the medicines best suited to their treatment – from ‘a simple genomic screen’.

Sparks and fellow director of investor relations Lauren Swales also discuss the importance of AstraZeneca’s $39bn acquisition of US biotechnology group Alexion, how Covid-19 has impacted the company’s focus on vaccines, and the areas of the business generating the most excitement.

AstraZeneca was crowned the winner of the Citywire Elite Companies Awards’ Emea drug manufacturers category.

 


Leave a comment